Applied Therapeutics 주식 (NASDAQ: APLT)

에 대한 최신 뉴스 Applied Therapeutics (NASDAQ:APLT) 주식

Applied Therapeutics

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics Inc

Baird analyst William Power maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Neutral and raises the price target from $70 to $100.

News

Price Target

Analyst Ratings

PLTR

Baird Maintains Neutral on Palantir Technologies, Raises Price Target to $100

WIIM

Pentair shares are trading lower after the company issued Q1 and FY25 adjusted EPS guidance below estimates.

Barclays analyst Richard Hightower maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Equal-Weight and lowers the price target from $59 to $56.

Barclays Maintains Equal-Weight on Realty Income, Lowers Price Target to $56

In December, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows" rel="noreferrer noopener">Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss</a>
In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's side effects, dosing protocol, and effectiveness compared to Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Zepbound (Mounjaro)</a>.
Five patients from the REDEFINE-1 and REDEFINE-4 trials interviewed by Reuters said CagriSema helped them lose weight rapidly, but side effects, such as nausea, constipation, and fatigue, were significant.
The weaker-than-expected trial data has raised doubts about Novo Nordisk's ability to compete with Eli Lilly's weight-loss drug.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
A key issue emerging from the trial is that only 57.3% of patients reached the highest dose of CagriSema. Novo has not clarified whether this was due to intolerable side effects or effective weight loss at lower doses.
Investors and analysts were also surprised by the study's flexible dosing protocol, which allowed participants to adjust their dosage instead of following a strict schedule.
Some believe this contributed to the low uptake of the highest dose and may have affected overall trial results.
Novo Nordisk will release its fourth quarter 2024 earnings on Wednesday. Analysts expect sales of DKK 79.73 billion and EPS of DKK 5.86 as per data from <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Benzinga Pro</a>.
Reuters, citing a Barclays analyst, noted that the lack of clarity has fueled negative sentiment, with concerns that CagriSema may be less effective than Eli Lilly's Zepbound, have worse tolerability, and be more difficult to manufacture.
Last week, Novo Nordisk&nbsp;released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" rel="noreferrer noopener">20mg (36 weeks)</a>.
Price Action: At last check on Tuesday, NVO stock was down 0.94% to $81.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43444040/dan-loebs-third-point-trims-amazon-microsoft-meta-as-tech-stocks-climb" target="_blank" rel="noreferrer noopener">Dan Loeb's Third Point Trims Amazon, Microsoft, Meta As Tech Stocks Climb</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Media

General

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

ARMK

Aramark shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) reported quarterly earnings of $2.72 per share. This is a 45.45 percent increase over earnings of $1.87 per share from the same period last year. The company reported $749.500 million in sales this quarter. This is a 18.14 percent increase over sales of $634.400 million the same period last year.

Earnings

IESC

IES Hldgs Q1 2025 Adj. EPS $2.72 Up From $1.87 YoY, Sales $749.500M Up From $634.400M YoY

Baird analyst Andrew Wittmann maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Outperform and lowers the price target from $125 to $117.

Baird Maintains Outperform on AECOM, Lowers Price Target to $117

CNH Industrial shares are trading lower after the company issued FY25 adjusted EPS results below estimates.

Cybersecurity provider Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) shares are trading higher premarket on Tuesday. The company disclosed enhanced capabilities for its Infinity Platform, which aim to accelerate zero-trust adoption, bolster threat prevention, reduce complexity,<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43455281/check-point-announces-new-ai-powered-innovations-to-bolster-unified-security-management-for-the-in" rel="noreferrer noopener"> and streamline security operations</a>.
By integrating AI and identity awareness, administrators can enforce more precise security policies, granting access only to authorized users.
Centralized visibility and policy analysis across environments help security teams uphold compliance and maintain strong security practices.
Nataly Kremer, Chief Product Officer at Check Point, said, &#8220;We are pleased to introduce several new AI-powered Innovations that cut down complexity and strengthen the Unified Security Management capabilities of the Infinity Platform.&#8221;
&#8221;Our customers will experience enhanced threat prevention, while finding it very easy to collaborate with third-party products.&#8221;
Last month, the company reported fiscal fourth-quarter revenue growth of 6% year-on-year to $703.70 million, topping the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43347093/check-point-q4-earnings-revenue-and-eps-beat-security-subscriptions-surge-expands-cybersecurity-offerings-despite-margin-pressure" rel="noreferrer noopener">consensus estimate of $698.82 million</a>.&nbsp;
The American Israeli enterprise security solution&nbsp;provider&#8217;s&nbsp;adjusted EPS of $2.70 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.66</a>.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify BlueStar Israel Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITEQ#NYSE">ITEQ</a>) and VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>).
Price Action: CHKP shares are up 0.67% at $215.30 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43455908" target="_blank" rel="noreferrer noopener">Dogecoin Regains Momentum After &#8216;Black Sunday&#8217; Rout—Here&#8217;s What Indicators Signal About The Memecoin&#8217;s Next Moves</a></li>
</ul>
Image via Shutterstock.

Equities

CHKP

ISRA

ITEQ

Check Point Boosts Threat Prevention with Upgraded Infinity Platform

Barclays analyst Richard Hightower maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Overweight and lowers the price target from $48 to $46.

Barclays Maintains Overweight on NNN REIT, Lowers Price Target to $46

Vodafone Group shares are trading lower after the company reported Q3 financial results.

ZENA

ZenaTech Inks LOI To Acquire A Fifth Land Survey Company In Southeast Florida

REGN

Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Outperform and raises the price target from $48 to $54.

TWST

Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $54

Guidance

ATI Sees Q1 2025 Adj. EPS $0.55-$0.61 Vs $0.48 Estimate; Sees FY25 Adj. EPS $2.80-$3.00 Vs $2.88 Estimate

ATI Sees Q1 2025 Adj. EBITDA $170M-$180M; Sees FY25 Adj. EBITDA $800M-$840M

Jefferies analyst Omar Nokta maintains Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) with a Hold and maintains $23 price target.

FLNG

Jefferies Maintains Hold on Flex LNG, Maintains $23 Price Target

RACE

Ferrari shares are trading higher after the company reported better-than-expected Q4 financial results.

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $14 price target.

CLGN

D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target

The Company expects full year 2025 free cash flow conversion of 90% or greater on adjusted net income.

HUBB

Hubbell Expects FY25 Adj. EPS Of $17.35 - $17.85 (Est $17.70); Anticipates Total Sales Growth And Organic Sales Growth Of 4% - 5%

Applied Therapeutics appoints Johnson as Executive Chairman, CEO steps down

The latest announcement is out from Applied Therapeutics ( ($APLT) ). Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairma...

Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles

RBC Capital analyst Brian Abrahams lowered the firm's price target on Applied Therapeutics (APLT) to $1.50 from $4 and keeps a Sector Perform ratin...

Applied Therapeutics price target lowered to $1.50 from $4 at RBC Capital

Applied Therapeutics (APLT – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The company's s...

William Blair downgrades Applied Therapeutics (APLT) to a Hold

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-ti...

Applied Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform without a price target While the management turnover "was a ...

William Blair downgrades Applied Therapeutics on revenue uncertainty

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Despegar.com&nbsp;(DESP) up 33% after Prosus annou...

Morning Movers: Despegar surges following deal to be acquired by Prosus

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Members of the Nordstrom family ...

Nordstrom family to take chain private: Morning Buzz

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), Vertex ...

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

ACRS

APLT

AVXL

DESP

ENGN

EXEL

GCMG

HNDAF

IIPR

LAES

MEOBF

MESO

MSTR

NSANF

NSANY

ORKA

PLYA

PONY

RGTI

SMTI

VRTX

VVOS

WULF

XELB

Legal

Press Releases

Kessler Topaz Meltzer & Check, LLP - APLT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. (APLT)

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT

Applied Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - APLT

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc.(APLT) Shareholders

Deadline Alert: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Applied Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 18, 2025 Deadline to file Lead Plaintiff Motion

Applied Therapeutics, Inc. (APLT) Investors: February 18, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Kirby McInerney LLP Urges Investors in Applied Therapeutics, Inc. (APLT) to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kaspi, Applied Therapeutics, Cassava, and MGPI and Encourages Investors to Contact the Firm

Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT

Comments

Applied Therapeutics

뉴스

에 대한 최신 뉴스 Applied Therapeutics (NASDAQ:APLT) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌